- Supplier site
- Group of sites (click to zoom)
Scientist.com supplier network (site locations)
Research supplier
Orphagen
Orphagen is listed as a small business research supplier in the Scientist.com network, with 1 site in 1 country.
Sign in to Scientist.com to open this supplier in your organization's marketplace.
Search companies, drugs, suppliers and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Services
What this research supplier says it provides, as listed in the Scientist.com network.
Type of company: Small business
In Vitro Assays
- Assay Development Construct or create new assays or modify existing ones.
- Cell Based Assays Apply compounds to cells and test for cellular phenotypes and effects on gene expression
- Cell Based Assays Consulting Expert advice to evaluate the functions of specific chemicals based on their constructions and systems.
- HTS Assay Development Develop assays to use in high throughput screening.
- Luciferase Reporter Assay Evaluate promoter activity by measuring light output from the luciferase enzyme.
In Vitro Pharmacology
- Nuclear Receptor Assays Measure nuclear receptor activity in biochemical and cell assays.
- Target Validation Demonstrate that modification of target activity has potential therapeutic benefits.
Where it operates
Sites by country, with the cities in each.
-
United States 1 site
About this supplier
In the supplier's own words, as listed in the Scientist.com network.
Orphagen addresses the pharmaceutical industry's need for new classes of drugs that have novel therapeutic mechanisms. We recognize that patients need genuinely new therapies rather than incremental improvements over existing ones. Our strength is our ability to identify drug-like small molecules that regulate novel drug targets, so-called orphan receptors that are not yet part of mainstream pharmaceutical drug discovery. Our name, “Orphagen”, is based on this expertise. We became an industry leader for our first therapeutic target, in autoimmune disease, and formed a long-term strategic...
Show the full description
Orphagen addresses the pharmaceutical industry's need for new classes of drugs that have novel therapeutic mechanisms. We recognize that patients need genuinely new therapies rather than incremental improvements over existing ones.
Our strength is our ability to identify drug-like small molecules that regulate novel drug targets, so-called orphan receptors that are not yet part of mainstream pharmaceutical drug discovery. Our name, “Orphagen”, is based on this expertise. We became an industry leader for our first therapeutic target, in autoimmune disease, and formed a long-term strategic partnership for this target in 2008 with Japan Tobacco. We have active internal drug discovery programs in several other therapeutic areas and look for both investors and partners to advance these programs.
- Website
- www.orphagen.com
Work with Orphagen on Scientist.com
For prices, more details, or to contact Orphagen, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.